Intech Investment Management LLC Sells 7,662 Shares of Repligen Co. (NASDAQ:RGEN)

Intech Investment Management LLC trimmed its position in Repligen Co. (NASDAQ:RGEN) by 81.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,803 shares of the biotechnology company’s stock after selling 7,662 shares during the quarter. Intech Investment Management LLC’s holdings in Repligen were worth $268,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Andra AP fonden acquired a new stake in shares of Repligen in the second quarter valued at approximately $25,000. International Assets Investment Management LLC acquired a new position in Repligen in the 2nd quarter valued at $33,000. UMB Bank n.a. lifted its position in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 130 shares during the period. Blue Trust Inc. grew its holdings in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Finally, nVerses Capital LLC bought a new position in shares of Repligen in the third quarter worth $45,000. Institutional investors own 97.64% of the company’s stock.

Insiders Place Their Bets

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.20% of the company’s stock.

Repligen Stock Down 4.6 %

Shares of NASDAQ:RGEN opened at $142.26 on Friday. The firm has a fifty day moving average price of $141.38 and a two-hundred day moving average price of $142.15. The company has a market cap of $7.97 billion, a price-to-earnings ratio of -384.48, a PEG ratio of 4.47 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a one year low of $113.50 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.23 earnings per share. Analysts anticipate that Repligen Co. will post 1.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Wells Fargo & Company began coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price for the company. Royal Bank of Canada restated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Wolfe Research assumed coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.